8.87MMarket Cap-0.27P/E (TTM)
0.1400High0.1202Low2.16MVolume0.1400Open0.1386Pre Close279.88KTurnover3.45%Turnover RatioLossP/E (Static)68.75MShares0.620052wk High3.07P/B8.08MFloat Cap0.120252wk Low--Dividend TTM62.61MShs Float836.0000Historical High--Div YieldTTM14.29%Amplitude0.1202Historical Low0.1290Avg Price1Lot Size
AIM ImmunoTech Stock Forum
AIM ImmunoTech Announces That It Will Not Proceed With an Offering Pursuant to Its Registration Statement on Form S-1 Until After It Files Its Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2024
4X Immune Response: AIM's Ampligen Breakthrough with AstraZeneca's FluMist Against Bird Flu
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaks
Friday, 7th February at 8:50 am
OCALA, Fla., Feb. 07, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: AIM) ("AIM" or the "Company") today announced its initiation of a plan to advance Ampligen as a vaccine adjuvant for avian influenza as part of the Company's antiviral priorit...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
AIM had news and didn't run which also happened with IVVD and CPIX. Both were held down, shorted and eventually ran. They ran the same day though so not sure about AIM but worth the watch!
$AIM ImmunoTech (AIM.US)$
I still have my eyes on KTTA - news was released today and it didn't really run. It got beaten down so could still see its day, or maybe not lol.
$Pasithea Therapeutics (KTTA.US)$
Remember, chasing is a dangerous game. Be very selective with...
Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
Wednesday, 5th February at 8:00 am
Safety Committee approval based on positive Phase 1 safety data demonstrating the combination therapy to be generally well-tolerated with no severe treatment-related adverse events or dose-limiting toxicities
Enrollment for Phase 2 expected to commence im...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY,...
No comment yet